| Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy R Seiler, HAD Ashab, N Erho, BWG van Rhijn, B Winters, J Douglas, ... European urology 72 (4), 544-554, 2017 | 809 | 2017 |
| The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex JR Prensner, MK Iyer, A Sahu, IA Asangani, Q Cao, L Patel, IA Vergara, ... Nature genetics 45 (11), 1392-1398, 2013 | 745 | 2013 |
| Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy N Erho, A Crisan, IA Vergara, AP Mitra, M Ghadessi, C Buerki, ... PloS one 8 (6), e66855, 2013 | 687 | 2013 |
| The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer D Chakravarty, A Sboner, SS Nair, E Giannopoulou, R Li, S Hennig, ... Nature communications 5 (1), 5383, 2014 | 614 | 2014 |
| Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study E Lalonde, AS Ishkanian, J Sykes, M Fraser, H Ross-Adams, N Erho, ... The lancet oncology 15 (13), 1521-1532, 2014 | 396 | 2014 |
| Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population RJ Karnes, EJ Bergstralh, E Davicioni, M Ghadessi, C Buerki, AP Mitra, ... The Journal of urology 190 (6), 2047-2053, 2013 | 357 | 2013 |
| Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy SG Zhao, SL Chang, N Erho, M Yu, J Lehrer, M Alshalalfa, C Speers, ... JAMA oncology 3 (12), 1663-1672, 2017 | 283 | 2017 |
| RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1 JR Prensner, S Zhao, N Erho, M Schipper, MK Iyer, SM Dhanasekaran, ... The lancet oncology 15 (13), 1469-1480, 2014 | 276 | 2014 |
| Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate-and high-risk men AE Ross, MH Johnson, K Yousefi, E Davicioni, GJ Netto, L Marchionni, ... European urology 69 (1), 157-165, 2016 | 270 | 2016 |
| Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis SG Zhao, SL Chang, DE Spratt, N Erho, M Yu, HAD Ashab, M Alshalalfa, ... The lancet oncology 17 (11), 1612-1620, 2016 | 223 | 2016 |
| Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome S You, BS Knudsen, N Erho, M Alshalalfa, M Takhar, H Al-deen Ashab, ... Cancer research 76 (17), 4948-4958, 2016 | 181 | 2016 |
| The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target SG Zhao, J Lehrer, SL Chang, R Das, N Erho, Y Liu, M Sjöström, RB Den, ... JNCI: Journal of the National Cancer Institute 111 (3), 301-310, 2019 | 174 | 2019 |
| High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program DP Labbé, G Zadra, M Yang, JM Reyes, CY Lin, S Cacciatore, EM Ebot, ... Nature communications 10 (1), 4358, 2019 | 160 | 2019 |
| Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes SA Tomlins, M Alshalalfa, E Davicioni, N Erho, K Yousefi, S Zhao, ... European urology 68 (4), 555-567, 2015 | 158 | 2015 |
| A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy AE Ross, FY Feng, M Ghadessi, N Erho, A Crisan, C Buerki, D Sundi, ... Prostate cancer and prostatic diseases 17 (1), 64-69, 2014 | 154 | 2014 |
| Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis B Benzon, SG Zhao, MC Haffner, M Takhar, N Erho, K Yousefi, P Hurley, ... Prostate cancer and prostatic diseases 20 (1), 28-35, 2017 | 152 | 2017 |
| Development and validation of a 28-gene hypoxia-related prognostic signature for localized prostate cancer L Yang, D Roberts, M Takhar, N Erho, BAS Bibby, N Thiruthaneeswaran, ... EBioMedicine 31, 182-189, 2018 | 149 | 2018 |
| Prostate cancer radiomics and the promise of radiogenomics R Stoyanova, M Takhar, Y Tschudi, JC Ford, G Solórzano, N Erho, ... Translational cancer research 5 (4), 432, 2016 | 146 | 2016 |
| Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer A Urbanucci, SJ Barfeld, V Kytölä, HM Itkonen, IM Coleman, D Vodák, ... Cell reports 19 (10), 2045-2059, 2017 | 139 | 2017 |
| TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup DP Labbé, CJ Sweeney, M Brown, P Galbo, S Rosario, KM Wadosky, ... Clinical Cancer Research 23 (22), 7072-7083, 2017 | 119 | 2017 |
Elai DavicioniVeracyteVerified email at veracyte.com
